

Eudipharm is part of a consortium called PharmaTrain (22 European universities), which aims to harmonize Masters of Pharmaceutical Medicine in Europe. Our program is based on the PharmaTrain syllabus and leads to a Master in Medicines Development (MMD).

THE FIRST YEAR OF EUDIPHARM

The first year of Eudipharm includes six base modules and a six-month internship. It is aimed at preparing students wishing to become professionals in the healthcare industry, CROs, or regulatory bodies, or to work as faculty or researchers in higher education institutions or as principal investigators in private or public practice.

THE SECOND YEAR OF EURDIPHARM

The second year of Eudipharm includes four extension modules and at least two elective modules. Successful completion of both years leads to a Master of Medicines Development (MMD).

All courses are taught in English.

The choice of "A la carte" elective modules is adapted to healthcare industry needs.

The aim is to provide continuing professional development for those wishing to update their knowledge or to acquire new expertise through the continuing pharmaceutical medicine education program.

An up-to-date training in the healthcare industry. The pharmaceutical industry is becoming more and more international. Globalization and the harmonization of regulatory requirements (ICH) for medicinal products between developed countries have progressively led to the pre-clinical and clinical development of drugs worldwide. This has resulted in complex, integrated development and registration strategies. The healthcare industry is open to graduates who have acquired needed skills during this pharmaceutical medicine program.

APPLICANTS

- 1) Post-graduate students with a background in Medicine, Pharmacy, Dentistry, Veterinary Medicine, Pharmacology, Biochemistry, or Molecular Biology.
- 2) Professionals from the healthcare industry, medicines agencies /regulatory bodies, CROs, and universities.

MODULES

Base modules

- Introductory Module, Principles of Discovery of Medicine and Development Planning
- Non-Clinical Testing, Pharmaceutical and Early Clinical Development
- Exploratory and Confirmatory Clinical Development
- Clinical Trials
- Regulatory Affairs; Drug Safety & Pharmacovigilance
- Healthcare Marketplace; Economics of Healthcare

Extension modules

- Biologicals
- Special Populations Trial Practice
- Pharmacoepidemiology Drug Safety Surveillance
- Pharmacoeconomics Markets
- 2 Elective Modules

"A LA CARTE"

Elective modules

- Biomarkers & Surrogate Endpoints
- Clinical Project Management
- Drug Development in Children
- Drug Evaluation in Rare Diseases
- Ethics & Legal Issues
- Generics & Biosimilars
- Geriatrics
- Medicine Regulation
- Meta-Analysis
- Modeling & Simulation
- Pregnancy & Medications

Universities

University of Manchester · University Claude Bernard Lyon, F · University of Dordrecht, NL · University of Sheffield, UK · University of Malta · National Veterinary School of Lyon, F · Semmelweis University, Budapest, H · University of Lille 2, F · University of Lisboa, P · Center of Pharmacovigilance (HCL, Lyon), F · Albert Schweitzer Academic Hospital, NL · International firms Altanapharma, G · Novartis, F · GCPA, Kessel-Lo, B · Medibridge, F · Madesco International BVBA, B · Product Life, F · Pharmagenesis, USA · Sanofi Pasteur MSD, F · Novartis Pharma AG, CH · The Degge Group Ltd, USA · IRIS, F · Hoffman-La Roche, CH · Federal Institute for Drugs and medical Devices, G · Exprimio LLP, UK · PFIZER, F · Clininfo, F · Innate Pharma, F · Merck Sharp Dohme-Clibret, F.

➡ For more information, please visit our website: www.eudipharm.net